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Tumour recurrence frequently occurs after radiotherapy, but the characteristics, intratumoural 
localization and post-irradiation behaviour of radioresistant cancer cells remain largely unknown. 
Here we develop a sophisticated strategy to track the post-irradiation fate of the cells, which 
exist in perinecrotic regions at the time of radiation. Although the perinecrotic tumour cells are 
originally hypoxia-inducible factor 1 (HIF-1)-negative, they acquire HIF-1 activity after surviving 
radiation, which triggers their translocation towards tumour blood vessels. HIF-1 inhibitors 
suppress the translocation and decrease the incidence of post-irradiation tumour recurrence. 
For the first time, our data unveil the HIF-1-dependent cellular dynamics during post-irradiation 
tumour recurrence and provide a rational basis for targeting HIF-1 after radiation therapy. 
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A
berrantly  accelerated  proliferation  and  metabolism  are   
typical  characteristics  of  cancer  cells1,  which  lead  to  an 
imbalance between oxygen supply and oxygen consumption 
in a solid tumour and cause a tumour-specific microenvironment, 
hypoxia2,3.  Clinical  studies  using  a  computerized  polarographic 
needle  electrode  have  revealed  that  in  malignant  tumours,  such   
as uterine cervix cancer, head-and-neck cancer and breast cancer, 
overall median partial oxygen pressure (pO2) is about 10 mm Hg   
and the overall hypoxic fraction (pO2  < or = 2.5 mm Hg) is ~25%  
(ref. 4). In contrast, pO2 values lower than 12.5 mm Hg were not 
found in normal tissues, such as normal breast tissue5. Immunohis-
tochemical analyses with markers have clarified the intratumoural 
localization of hypoxia in detail6. Because of the limited distance 
molecular  oxygen  can  diffuse,  most  malignant  tumours  grow 
individually as a conglomerate of so-called ‘micro tumour cords’, 
in each of which a blood vessel is surrounded by well-oxygenated 
(normoxic), then oxygen-insufficient (hypoxic), and finally oxygen- 
depleted  (anoxic/necrotic)  cancer  cells2,7.  In  addition  to  such 
chronic hypoxia, acute hypoxia is known to develop even proxi-
mal to blood vessels as a result of the transient functional failure/
occlusion of blood vessels8,9.
Hypoxia achieves many of its effects through the activation of a 
transcription factor, hypoxia-inducible factor 1 (HIF-1). HIF-1 is a 
heterodimer composed of an α-subunit (HIF-1α) and a β-subunit 
(HIF-1β), and its activity is mainly dependent on the stability and 
modification of HIF-1α10. Under normoxic conditions, the oxygen-
dependent degradation (ODD) domain of HIF-1α is hydroxylated 
by prolyl hydroxylases and ubiquitinated by a pVHL-containing E3 
ubiquitin ligase, resulting in rapid proteolysis of the subunit11,12. 
Under  hypoxic  conditions,  however,  HIF-1α  is  stabilized  and 
interacts with HIF-1β10. The resultant heterodimer, HIF-1, binds 
to its cognate enhancer sequence, the hypoxia-responsive element 
(HRE), and induces the expression of various genes responsible 
for ‘adaptation of cellular metabolism to hypoxia (the switch from   
oxidative  to  anoxic  respiration)  (ref.  13)’,  ‘escape  from  hypoxia 
(invasion and metastasis of cancer cells) (refs 14,15)’, and ‘improve-
ment of hypoxia (angiogenesis) (refs 16,17)’.
The radioresistance of individual cancer cells is known to be 
influenced by various intrinsic and extrinsic factors, and therefore 
is highly dissimilar in diverse and heterogeneous tumour microen-
vironments. Accumulated evidence has suggested that one of the 
most influential factors is hypoxia2,3,18,19. Depletion of oxygen is 
reported to directly disturb radiation-induced production of reac-
tive and cytotoxic species (chemical oxygen effect)8,19. Moreover, 
hypoxia is known to induce tumour radioresistance through the 
activation of HIF-1 (biological oxygen effect)20–23. Consistent with 
these findings, there is clinical evidence that both the size of the 
intratumoural hypoxic fraction and the level of HIF-1α correlate 
with a poor prognosis after radiation therapy4,24,25.
However, regarding the dynamic changes of the tumour micro-
environment during tumour growth and after radiation therapy, 
problems  in  hypoxia-mediated  radioresistance  seem  to  be  more 
complicated.  Immunohistochemical  analysis  with  both  an  anti-
HIF-1α  antibody  and  a  hypoxia  marker,  pimonidazole,  recently 
revealed that HIF-1α-positive cells are not necessarily stained with 
pimonidazole26,27. Namely, in some types of malignant tumours, 
chronic  hypoxia  can  be  histologically  categorized  into  two  sec-
tors:  HIF-1α-positive/pimonidazole-negative  and  pimonidazole-
positive/HIF-1α-negative. This fact has repeatedly been confirmed 
in various human tumours as well as tumour xenografts26–28. More-
over, immunostaining combined with optical real-time imaging for 
HIF-1 activity revealed that ionizing radiation dramatically alters 
the distribution of oxygen and nutrients in a solid tumour, trigger-
ing a transient decrease and subsequent increase in intratumoural 
HIF-1 activity20,29–31. Because of these spatiotemporal complexi-
ties, how, when, and where the radiochemical and radiobiologi-
cal  mechanisms  function  in  tumour  radioresistance  are  largely 
unknown. Moreover, the characteristics, intratumoural localization, 
and post-irradiation dynamics of radioresistant cancer cells have 
not been clarified yet.
To address these issues, we established a strategy to separately tag 
HIF-1α-positive/pimonidazole-negative  cells  and  pimonidazole-
positive/HIF-1α-negative cells at a precise window in time. Sub-
sequent cell-tracking experiments revealed that the pimonidazole-
positive/HIF-1α-negative cancer cells survive radiation better than 
their counterparts. Moreover, we demonstrate for the first time, that 
the surviving cells acquire high levels of HIF-1 activity in areas of 
radiation-induced reoxygenation and translocate towards tumour 
blood vessels after radiation therapy.
Results
A  strategy  to  tag  hypoxic  cells  with  luciferase  protein.  Cells 
can  be  genetically  tagged  with  marker  proteins  through  site-
specific recombination by Cre recombinase32–34. We generated a 
gene  construct,  CAGp/loxP-polyA-loxP-luciferase,  that  results  in 
luciferase  expression  after  Cre-mediated  deletion  of  the  poly  A 
signal flanked by loxP sites (Fig. 1a). After co-transfection of the 
construct  with  CMVp-Cre  that  constitutively  expresses  Cre  into 
human  embryonic  kidney  293  cells  (Fig.  1b,  upper),  luciferase 
was expressed regardless of oxygen tension (Fig. 1c). To generate 
a cell that would persistently express luciferase after experiencing 
hypoxia, we generated a hypoxia-inducible expression vector for 
Cre.  We  previously  showed  that  HIF-1-dependent  expression  of 
arbitrary genes of interest could be obtained by a dual strategy, in 
which the artificial HIF-1-dependent promoter including 5 copies 
of  HRE  (5HREp)  is  responsible  for  the  expression  of  a  fusion 
protein composed of the product of a gene of interest and the ODD 
domain of HIF-1α35. The 5HREp/Cre–ODD gene, which expresses 
a Cre–ODD fusion protein under the control of HIF-1 (Fig. 1b, 
middle),  induced  luciferase  expression  from  CAGp/loxP-polyA-
loxP-luciferase under hypoxic but not normoxic conditions (Fig. 1c). 
To add temporal specificity, we applied the Cre-ERT2 technique32,33, 
in which Cre-ERT2 translocates into the nucleus and induces site-
specific  recombination  only  in  the  presence  of  tamoxifen.  We 
generated  a  construct,  5HREp/Cre-ERT2–ODD  (Fig.  1b,  lower), 
which  expressed  Cre-ERT2–ODD  under  hypoxic  conditions   
(Fig. 1d). The stable transfectant containing both CAGp/loxP-polyA-
loxP-luciferase  and  5HREp/Cre-ERT2–ODD  expressed  detectable 
luciferase bioluminescence 16 h after tamoxifen treatment under 
hypoxic but not normoxic conditions (Fig. 1e). Estrogen did not 
induce luciferase activity under hypoxic conditions (Fig. 1c). Site-
specific recombination was first detected at 16 h and peaked 24 h after 
tamoxifen treatment under hypoxia (Fig. 1f). Luciferase-tagging did 
not occur when HIF-1α expression was not fully induced either at 
3% O2 or under glucose-deprived conditions at 1 and 0.02% O2 
(Supplementary  Fig.  S1a–c).  The  luciferase-tagging  was  almost 
completely abrogated by HIF-1α downregulation (Supplementary 
Fig. S1d–f), or by treatment with a cell cycle inhibitor, hydroxyurea 
(Supplementary  Fig.  S1g–i).  These  results  indicate  that  the 
luciferase-tagging was dependent on both HIF-1 activity and DNA 
replication. Taken together, these results document a tamoxifen-
inducible luciferase-tagging strategy for HIF-1-active cells based on 
Cre-ERT2/loxP site-specific recombination.
Luciferase-tagging  of  hypoxic  cells  in  tumour  xenografts.  To   
test the tagging strategy in vivo, we administered tamoxifen once   
to  nude  mice  bearing  subcutaneous  tumour  xenografts  of  the   
stable  transfectant  with  5HREp/Cre-ERT2–ODD  and  CAGp/loxP-
polyA-loxP-luciferase. Luciferase bioluminescence was detected on 
the first day after the single tamoxifen injection (Fig. 2a,b). Immu-
nohistochemical staining of frozen tumour sections with both anti-
HIF-1α antibody (red fluorescence) and anti-luciferase antibody ARTICLE     
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(green  fluorescence)  detected  the  existence  of  cells  with  yellow   
colour, indicating co-localization of HIF-1α and luciferase proteins 
in regions distant from perfusion-positive blood vessels on the first 
day (Fig. 2c–e). Thus, this novel technology was able to tag HIF-
1-active hypoxic cells with luciferase in a xenograft tumour after 
tamoxifen administration. We confirmed that treatment of cells with 
various acute/intermittent/cycling hypoxia in vitro, which induced 
transcriptional  activity  of  HIF-1,  as  reported  previously36–38,   
did not lead to luciferase-tagging because of the arrest of the cell 
cycle (Supplementary Fig. S2), suggesting that the system efficiently 
tag perfusion-limited chronic hypoxia rather than acute hypoxia 
in vivo. Moreover, we revealed that the tamoxifen concentration in 
blood reached a maximum at 2 h after the drug’s administration but 
dramatically decreased to about 10% by 24 h later (Supplementary 
Fig. S3). The rapid clearance enabled us to specifically tag HIF-1-
positive cells with luciferase in vivo at a precise window in time 
(approximately within 24 h after tamoxifen administration).
Tracking the fate of hypoxic cells during tumour growth. Because 
the site-specific recombination of our system occurs in the genomic 
DNA, the change will be inherited in all daughter cells, allowing us 
to follow the fate of tagged cells during tumour growth. After the 
tagging of HIF-1-active cells with luciferase on the first day after 
tamoxifen treatment, the number of luciferase-positive cells was 
reduced dramatically (Fig. 2c–e). To analyse the mechanism behind 
the  reduction  in  more  detail,  we  examined  the  spatio-temporal 
relationship between luciferase-tagged cells, HIF-1α-positive cells, 
and pimonidazole-positive cells over time (Fig. 3a). Double stain-
ing of sections with anti-HIF-1α and anti-pimonidazole antibodies 
showed that hypoxic regions were composed of two distinct areas: a 
HIF-1α-positive/pimonidazole-negative area (HIF-1-positive area) 
and a pimonidazole-positive/HIF-1α-negative area (pimonidazole-
positive area). The HIF-1-positive area was closer to blood vessels, 
on average, than the pimonidazole-positive area in a tumour cord, 
consistent with previous reports26,27 (Fig. 3a,b). It should be noted 
that HIF-1α is not usually expressed in perinecrotic/ischemic areas 
probably because of depletion of glucose at least in part (Supple-
mentary Fig. S1a). Distances ‘between pimonidazole-positive cells 
and  blood  vessels’  and  ‘between  HIF-1-positive  cells  and  blood   
vessels’ were constant over time, meanwhile that ‘between luciferase-
tagged cells and blood vessel’ gradually increased during the obser-
vation (Fig. 3a,b). The luciferase-tagged cells were predominantly in 
the HIF-1-positive area and not in the pimonidazole-positive area 
on the first day after the single tamoxifen administration (Fig. 3a,c; 
Supplementary Fig. S4). On the second day, the tagged cells were 
mainly in the pimonidazole-positive area. On the third day, few 
tagged cells remained in the HIF-1- or the pimonidazole-positive 
areas, but some were found in necrotic regions. These results reveal 
a shift of tumour cells from the HIF-1-positive area to the pimoni-
dazole-positive area, and further to necrotic regions during tumour 
growth. This represents a shift from moderately to severely hypoxic 
areas and explains why both luciferase bioluminescence (Fig. 2a,b) 
and luciferase-positive cells (Fig. 2c–e) dramatically decreased after 
the completion of luciferase-tagging in vivo.
Survival  of  perinecrotic  tumour  cells  after  radiation  therapy. 
Applying  the  tagging  technique,  we  examined  the  fate  of  each 
hypoxic  fraction  in  tumour  recurrence  after  radiation  therapy.   
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Figure 1 | Luciferase-tagging of hypoxic cells by HIF-1- and tamoxifen-dependent site-specific recombination. (a) schematic diagram of CAGp/ 
loxP-polyA-loxP-luciferase gene (upper) that results in luciferase expression after Cre-mediated deletion of floxed poly A signal (lower). (b) schematic 
diagrams of CMVp-Cre (upper; expressing Cre constitutively), 5HREp/Cre–ODD (middle; expressing Cre–oDD in a HIF-1-dependent manner), 5HREp/ 
Cre-ERT2–ODD (lower; expressing Cre-ERT2–oDD in a HIF-1-dependent manner) genes. (c) After transient transfection with the indicated gene constructs, 
cells were treated with ( + ) or without ( − ) estrogen or tamoxifen under normoxic or hypoxic conditions for 24 h and subjected to luciferase assay. 
mean ± s.d. n = 3. The statistical significance of differences was determined using student’s t-test. **P < 0.01. ns: not significant. (d) stable transfectant 
with the 5HREp/Cre-ERT2–ODD gene and CAGp/loxP-polyA-loxP-luciferase gene was treated with tamoxifen under normoxic or hypoxic conditions for  
the indicated period and subjected to immunoblotting using antibodies against HIF-1α, or the myc epitope tag for the Cre-ERT2–oDD fusion protein.  
(e) After normoxic (white rhombus) or hypoxic (black square) treatment for the indicated period, the stable cell was subjected to Luciferase assay. 
mean ± s.d. n = 3. **P < 0.01 (student’s t-test). (f) Genomic DnA was extracted after the same treatment as (e) and subjected to semi-quantitative 
genomic PCR assay. The sizes of the marker bands (base pair) are shown. The primers used in the PCR assay are shown in (a) as dotted arrows.ARTICLE
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We irradiated tumours with a single dose of 25 Gy either 1 day 
after the single tamoxifen administration, when the tagged cells 
were mainly in the HIF-1-positive area or 2 days later when they 
were mainly in the pimonidazole-positive areas (Fig. 3a,c; Supple-
mentary Fig. S4). At that dose, the tumours regressed and became   
non-palpable but later recurred (Fig. 4a). The bioluminescent inten-
sity in the recurrent tumours was much higher when the radiation 
had been given to the xenograft in which tagged cells were located 
in the pimonidazole-positive area rather than HIF-1-positive area 
(Fig.  4b,c).  Moreover,  immunohistochemical  analysis  (Fig.  4d,e)   
and  flow  cytometric  analysis  (Fig.  4f–h)  confirmed  that  there   
were more luciferase-tagged cells in the recurrent tumours after 
irradiation at 2 days, when the majority of the tagged cells were   
in  the  pimonidazole-positive  area  (57.4 ± 9.9%)  than  at  1  day,   
when they were in the HIF-1-positive area (14.6 ± 5.9%). Thus, the 
pimonidazole-positive  tumour  cells  were  more  likely  to  survive 
radiation therapy.
Because hypoxia is one of the most influential extrinsic factors 
to cellular radioresistance, we next examine the involvement of low 
oxygen concentration in radioresistance of pimonidazole-positive   
tumour  cells.  Immunocytochemistry  in  vitro  showed  that  cells 
were stained with pimonidazole at less than 1% oxygen but not at 
3% oxygen (Supplementary Fig. S5); therefore, the pimonidazole- 
positive layer in a tumour cord would be under such oxygen con-
ditions (Table 1). Meanwhile, the HIF-1-positive layer seems to be 
exposed to relatively mild hypoxia at least 1–3% oxygen, because 
our site-specific recombination did not occur in the presence of 3%  
oxygen (Supplementary Fig. S1a–c), and because HIF-1-positive cells 
were not stained with pimonidazole in vivo (Fig. 3a). Taken together, 
pimonidazole-positive layers are under severer hypoxia than HIF-
1-positive layers. Clonogenic cell survival assay showed that cells 
became  more  radioresistant  under  0.02%  severe  hypoxia  than   
2% mild hypoxia (Supplementary Fig. S6). Moreover, after radia-
tion treatment, most cancer cells were stained with a DNA damage 
marker, γH2AX, in normoxic areas, but seldom in pimonidazole- 
positive areas (Supplementary Fig. S7). All of these results indi-
cate that the decreased oxygen concentration is responsible for the   
radioresistance of pimonidazole-positive cells at least in part.
HIF-1-dependent translocation of radio-surviving tumour cells. 
We next analysed the tumour cells in the pimonidazole-positive 
area after irradiation in more detail. The xenografts were irradi-
ated (25 Gy) 2 days after tamoxifen treatment when the tagged cells 
were in the pimonidazole-positive area and subjected to immuno-
histochemical analysis 4 days later (Fig. 5a,b). In the un-irradiated 
tumours, the luciferase-tagged cells almost completely disappeared 
(Fig. 5b–d), consistent with the shedding observed above (Fig. 3). In 
contrast, in the irradiated tumours, tagged cells were present near 
perfusion-positive tumour blood vessels (Fig. 5b,e,f: radiation ( + ) 
& HIF-1 inhibitor ( − )). The same kind of results was confirmed   
in tumour xenografts of a human colon carcinoma cell line, WiDr 
(Fig. 5g,h). These results suggest that tumour cells in the pimoni-
dazole-positive area translocated closer to the functional tumour 
blood vessels after surviving radiation.
It has been reported that radiation leads to reoxygenation of 
tumours and eventually upregulates HIF-1α expression. Molecular 
mechanisms behind this phenomenon are multiple: (1) enhanced 
translation  of  HIF-1α  protein  in  a  PI3K-Akt/mTOR-dependent 
manner29,30, and (2) stabilization of HIF-1α protein through the 
decrease in hydroxylation of Pro402/564 by reactive oxygen20 and 
through the S-nitrosylation of Cys533 by NO generated in tumour-
associated macrophages39. Taking advantage of the tagging tech-
nique, we examined whether the upregulation of HIF-1α expression   
was critical for the translocation of the pimonidazole-positive cells. 
First, we irradiated the xenograft when tagged cells were present 
in  the  pimonidazole-positive  area,  and  performed  immunohis-
tochemistry the following day (Fig. 5i,j). The tagged cells disap-
peared in the non-irradiated tumour, but persisted and expressed 
HIF-1α in the irradiated tumour (Fig. 5j,k; Supplementary Fig. S8). 
In addition, we confirmed that inhibition of the radiation-induced   
upregulation of HIF-1 activity with the HIF-1 inhibitors, YC-1 (Sup-
plementary Fig. S9a,b)40 and Acriflavine41, dramatically reduced   
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the translocation of the tagged cells (Fig. 5b,e–h; Supplementary   
Fig. S9c,d) and suppressed tumour recurrence after radiation ther-
apy (Fig. 6a,b). All of these results indicate that, after surviving 
radiation, perinecrotic tumour cells in the pimonidazole-positive 
area translocate to the proximal regions of tumour blood vessels 
in a HIF-1-dependent manner, leading to the initiation of tumour 
recurrence (Supplementary Fig. S8). Finally, we examined possible 
involvement  of  epithelial–mesenchymal  transition  (EMT)  in  the 
translocation, because HIF-1 is known to provoke it and induce cell   
migration42,43. Increase in oxygen- and glucose-availability, which 
are known to activate HIF-1 in solid tumours after radiation ther-
apy,  shifted  the  expression  of  an  epithelial  marker  (E-cadherin)   
to that of mesenchymal markers (vimentin and N-cadherin) in a 
HIF-1-dependent manner, suggesting the function of EMT in the 
translocation (Supplementary Fig. S10).
Discussion
In the present study, we established a novel system to tag hypoxic 
cells in a tumour xenograft at a specific window in time. Exploit-
ing its advantages, we analysed the dynamics and fate of the cells 
during tumour growth and after radiation therapy. Here we suc-
cessfully revealed that the pimonidazole-positive/HIF-1α-negative 
cancer cells (pimonidazole-positive cells) survive radiation better 
than their counterparts. Moreover, we demonstrate, for the first 
time, that the cells acquire high levels of HIF-1 activity in areas of 
radiation-induced reoxygenation and translocate towards tumour 
blood vessels after surviving radiation therapy.
We previously reported that cancer cells which acquire HIF-1 
activity after radiation treatment protect the tumour vasculature 
from the cytotoxic effects of radiation by inducing the expression   
of  vascular  endothelial  cell-growth  factor30.  Here  we  identi-
fied pimonidazole-positive cells as the population that efficiently   
survive  radiation  and  acquires  significant  HIF-1  activity.  Taken 
together, these findings suggest that, by inducing HIF-1 activity, 
pimonidazole-positive  cancer  cells  not  only  protect  the  tumour   
vasculature but also translocate towards the blood vessels, facili-
tating both indirectly and directly local tumour recurrence after   
radiation.
The  mechanisms  behind  the  post-irradiation  translocation 
of perinecrotic cells to regions close to blood vessels still remain 
unclear. Radiation-induced damage of normoxic cells generates a 
pressure gradient to the less damaged hypoxic region that might 
contribute to the translocation of the surviving cells. Alternatively, 
the hypoxic cells might actively migrate towards the blood vessels. 
Actually, we confirmed that the increase in oxygen- and glucose-
availability, which are known to activate HIF-1 in solid tumours 
after radiation therapy, promoted EMT in a HIF-1-dependent man-
ner (Supplementary Fig. S10). The translocating cells would gain 
nutrients and oxygen through their proximity to the blood vessels, 
potentially  facilitating  tumour  recurrence.  The  HIF-1-dependent   
translocation/migration  of  the  surviving  cells  towards  radio- 
protected blood vessels might suggest a novel function of HIF-1 in 
both local tumour recurrence and distant tumour metastasis after 
radiation therapy.
To  directly  examine  the  involvement  of  HIF-1  in  the  post- 
irradiation translocation of perinecrotic cells, it was critical to inhibit 
the activation of HIF-1. Although the short interfering RNA tech-
nique is useful to specifically knockdown the expression of a target 
gene in general, we could not exploit it here because our tagging 
strategy is completely HIF-1-dependent (Supplementary Fig. S1d–f). 
Alternatively, we applied pharmacological inhibitors. Administra-
tion of the HIF-1 inhibitors, YC-1 (Fig. 5b,e–h) and acriflavine (Sup-
plementary Fig. S9c,d), significantly suppressed the post-irradiation   
translocation of perinecrotic cells towards the vasculature. It is rea-
sonable to conclude that these results were obtained through a com-
mon HIF-1-inhibiting effect, rather than a nonspecific/off-target 
effect, because the mechanisms of action of the drugs behind the 
HIF-1 blockade are completely different.
To  identify  intratumoural  localization  of  potential  radio- 
surviving cells, it is critical to understand the characteristics of cells, 
which were tagged with luciferase through the HIF-1-dependent 
Cre-ERT2/loxP system. It seems reasonable to assume that the tagged 
cells were under chronic hypoxia in the pimonidazole-positive sec-
tor, rather than acute hypoxia, because our in vitro data showed that 
treatment of cells with various acute/intermittent/cycling hypoxia, 
which  induced  HIF-1  activity36–38,  did  not  promote  luciferase- 
tagging (Supplementary Fig. S2). If so, our finding that 57.4 (9.9%) 
of  cells  were  tagged  with  luciferase  in  the  recurrent  tumour  is 
somewhat surprising, because multiple studies have suggested the 
importance of acute rather than chronic hypoxia in tumour radio-
resistance44.  However,  we  should  not  ignore  the  importance  of 
acute hypoxia, because there remains a possibility that other acute 
hypoxic conditions, which we have not yet reproduced owing to its 
complexity44,45, could have induced luciferase-tagging in vivo.
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So, what were the origins of luciferase-negative cells detected in 
the recurrent tumours after radiation treatment had been given to 
the xenografts, in which tagged cells existed in the pimonidazole-
positive sector? The origins seem to be multiple. One of the most 
reasonable answers is HIF-1-positive/luciferase-negative cells (Sup-
plementary Fig. S4). Another is acute/intermittent/cycling hypoxia 
because of the insufficient tagging of them. In addition, there is the 
possibility that normoxic tumour cells might have survived radia-
tion and caused the luciferase-negative cells to some extent because 
the radioresistance under hypoxia is no more than three times that 
under normoxia8. Furthermore, we could not exclude the possi-
bility that pimonidazole-positive/luciferase-negative hypoxia also 
caused the luciferase-negative cells in recurrent tumours because it 
is impossible to completely tag all of them with luciferase (Supple-
mentary Fig. S4). It is difficult to provide definitive answers because 
of the limitations of the tagging strategy.
Exploiting  the  results  of  our  study,  we  can  characterize  the 
microenvironments in each layer of a tumour cord (Table 1). Pimo-
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nidazole-positive layer and HIF-1-positive layer seem to be under 
severe ( < 1% oxygen) and relatively mild (1–3% oxygen) hypoxia, 
respectively,  as  described  above.  The  glucose-dependency  of  the 
luciferase-tagging in vitro (Supplementary Fig. S1a-c) suggests that 
HIF-1-positive  cells,  in  contrast  to  pimonidazole-positive  cells, 
are  present  under  glucose-available  conditions.  The  presence  of 
hydroxyurea  completely  inhibited  the  luciferase-tagging  in  vitro 
(Supplementary Fig. S1g-i), suggesting that the HIF-1-positive cells 
are still proliferating.
In the present study, we mainly used the HEK293 cell line that 
has no oncogenic mutations. This enabled us to assume that any 
phenomenon observed here was not dependent on oncogenic muta-
tions and that most cells fundamentally have the ability to behave 
identically  to  the  cells  after  radiation  treatment.  However,  one 
needs to understand the potential disadvantages of using these cells. 
HEK293 is no more than an experimentally transformed cell line, 
and, therefore, would not be necessarily a good model for cancer 
research. From this point of view, we should not simply suppose 
that the phenomena/mechanism observed here would be general. 
Although we have confirmed a colon carcinoma cell line, WiDr, to 
have the same potential as HEK293 cells for tumour translocation 
(Fig. 5g,h), it is critical to further perform the same cell-tracking 
experiments using various cancer cell lines.
Here we obtained enough information to understand how, when, 
and where ‘the low pO2-mediated radiochemical mechanism’ and 
‘the  HIF-1-dependent  radiobiological  mechanism’  function  in 
response to radiation therapy. The predominant survival of pimo-
nidazole-positive cells over the other populations can be simply 
explained by the radiochemical oxygen effect, because pO2 critical 
for efficient DNA damage by ionizing radiation is extremely low18,19 
(Table 1). Actually, the extent of DNA damage in pimonidazole-
positive cells was not so severe compared with that in the other 
cells  (Supplementary  Fig.  S7).  Following  the  survival,  radiation-
induced activation of HIF-1 is responsible for the translocation of 
the surviving cells towards tumour blood vessels, leading to tumour 
recurrence.  On  the  basis  of  these  findings,  both  radiochemical   
and radiobiological mechanisms should be inhibited for a better 
therapeutic effect.
In  addition  to  the  HIF-1-dependent  radiobiological  mecha-
nism,  there  are  other  biological  processes  that  potentially  affect 
radioresistance of hypoxic cells. It has been reported that hypoxia 
induces the expression of some cell cycle regulators46,47 and eventu-
ally influences radiosensitivity of cells. Moreover, chronic hypoxia, 
but not acute hypoxia, decreases the expression of genes related   
to DNA damage repair and increases cellular radiosensitivity48,49. 
So, to fully elucidate molecular mechanism behind radioresistance 
of perinecrotic tumour cells, it is critical to further analyse spatio-
temporal relationship among these biological processes in highly 
heterogeneous and dynamically changing tumour microenviron-
ments during tumour growth and after radiation therapy.
Methods
Cell culture and reagent. The human embryonic kidney cell line (HEK 293) and 
human colon adenocarcinoma cell line (WiDr) were purchased from American 
Type Culture Collection. Cells were maintained in 10% FBS-Dulbecco’s modified 
Eagle’s medium. Normoxic and hypoxic conditions were achieved in a well- 
humidified incubator with 5% CO2 and 95% air at 37 °C (O2 = 20%) and in a 
Bactron Anaerobic Chamber, BACLITE-2 (O2  < 0.02%; Sheldon Manufactur-
ing), respectively. Hypoxic conditions with 1 and 3% were achieved in a hypoxic 
workstation, INVIVO2-500 (Ruskinn). Estrogen (17β-estradiol; Sigma-Aldrich) 
and tamoxifen (4-Hydroxytamoxifen; Sigma-Aldrich) were dissolved in ethanol, 
and YC-1 in DMSO. Doses of tamoxifen and YC-1 in vivo were 5 mg kg − 1 and 
100 mg kg − 1, respectively.
Plasmid construct. To construct the plasmid encoding 5HREp/Cre-ERT2–ODD, 
the nuclear localization signal and luciferase gene in p5HRE–ODD-Luc35 were 
substituted with a Cre recombinase (Cre)–estrogen receptorT2 (ERT2) fusion gene 
and myc epitope tag-coding sequence, respectively. To construct the plasmid 
encoding 5HREp/Cre–ODD, the nuclear localization signal and luciferase gene 
in p5HRE–ODD-Luc35 were substituted with the Cre-coding sequence and myc 
epitope tag-coding sequence, respectively. To construct the plasmid encoding 
CMVp-Cre, which constitutively expresses Cre, the d2EGFP gene in pCMV-
d2EGFP50 was substituted with the Cre-coding sequence. To construct the plasmid 
encoding CAGp/loxP-polyA-loxP-luciferase, two loxP sites flanking the SV40 poly-
adenylation signal were inserted downstream of the constitutively active chicken 
β-actin promoter (CAGp) of pCAG1. The coding sequence for the firefly luciferase 
gene was additionally inserted downstream. See Fig. 1a,b for schematic diagrams  
of the constructs.
Stable transfectant. HEK 293 cells were stably transfected with two plasmids  
encoding the 5HREp/Cre-ERT2–ODD gene and the CAGp/loxP-polyA-loxP- 
luciferase gene, respectively, by the calcium phosphate method51. A representative 
clone, which showed HIF-1 and tamoxifen-dependent luciferase-tagging, was  
used in the present study.
Luciferase-tagging experiments in vitro. HEK 293 cells or their derivatives 
were seeded in 24-well plates (2×104 cells per well). For the experiment in Fig. 1c, 
the cells were transiently transfected with the indicated genes, and treated with 
estrogen or tamoxifen (100 nM) under normoxic (20% oxygen) or hypoxic (0.02% 
oxygen) conditions for 24 h. For the experiments in Fig. 1 d–f, the HEK293 stable 
transfectant was treated as described above. The cells were lysed with 100 µl of 
Passive lysis buffer (Promega) for luciferase assays using Luciferase assay reagent 
(Promega), according to the manufacturer’s instructions. For genomic PCR assays, 
genomic DNA was purified with a MagExtractor genome kit (Toyobo), and 1 µg 
of DNA was subjected to PCR with a KOD Plus kit (Toyobo) and the primers, 
which annealed to the CAGp and luciferase-coding sequence as schematically 
represented in Fig. 1a. Sequences of primers are 5′-ctttgtcccaaatctggcggagccgaaatc-
3′, and 5′-agcgtaagtgatgtccacctcgatatgtgc-3′. For immunoblotting, cell lysate was 
collected with 100 µl of 1×SDS–PAGE loading buffer, applied to SDS–PAGE, and 
reacted with anti-HIF-1α mouse monoclonal antibody (BD Bioscience; Working 
conc. = 0.5 µg ml − 1) and anti-myc-tag mouse monoclonal antibody (Cell Signaling 
Technology; ×2,000 dilution) for the detection of HIF-1α and Cre-ERT2–ODD, 
respectively. Proteins were detected using anti-mouse IgG horseradish peroxidase-
linked whole antibody (GE Healthcare Bio-Science) and an ECL-PLUS system  
(GE Healthcare), according to the manufacturer’s instructions.
Luciferase-tagging of hypoxic tumour cells in vivo. Stable cells (2×107 cells  
per 100 µL PBS) were subcutaneously transplanted into the right hind leg of  
immunodeficient mice (8-weeks old, male, BALB/c nu/nu; Shimizu Laboratory 
Supplies). For in vivo luciferase-tagging, the tamoxifen solution was injected once 
on day 0 into the footpad of the tumour-bearing right leg (5 mg kg − 1).
Radiation treatment in vivo. The tumour xenografts were locally irradiated  
with 25 Gy of 137Cs γ-rays using a Gammacell 40 Exactor (MDS Nordion  
International).
Optical imaging of luciferase activity in tumour xenografts. Optical imaging  
in vivo was carried out with an IVIS-200 (Caliper)29,30,35,52. Bioluminescent images  
Table 1 | Indirect characterization of the microenvironment in 
each layer of a tumour cord.
Normoxic cells Hypoxic cells
HIF-1-positive Pimonidazole-
positive
Distance from 
blood vessel
Close Far Extremely far
HIF-1α 
expression
 −   +   − 
Pimonidazole 
staining
 −   −   + 
Luciferase-
tagging
 −   +   − 
Glucose-
availability
 +   +   − 
oxygen 
concentration
>> 1% 1–3%  <  1%
Proliferation  +   +   − 
Radioresistance Very low Low High
Contribution to 
recurrence
 −   −   +  +  + ARTICLE
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were acquired just 3 min after the intravenous injection of the luciferin solution 
(200 µL of 5 mg ml − 1 solution). During the imaging, the mice were anaesthetized 
with 2.5% isoflurane gas in the oxygen flow (1.5 L per min). Signal intensity was 
quantified and analysed using Living Image 2.50-Igor Pro 4.90 software (Caliper).
Growth delay assay. Tumour volume was calculated as 0.5×length×width2, and 
compared with the initial value to calculate relative tumour volume.
Immunohistochemical analyses. Tumour xenografts were surgically excised 
90 min after an intraperitoneal injection with pimonidazole hydrochloride6  
(Natural Pharmacia; 60 mg kg − 1) and 1 min after an intravenous injection with 
Hoechst 33342 (100 µl of 10 mg ml − 1 solution; Invitrogen; especially in Figs 2c,d, 
4d, and 5b). Frozen sections of the xenografts were prepared with OCT compound 
(Sakura Finetek). Immunostaining was performed with anti-HIF-1α antibody  
(BD Bioscience; Working conc. = 2.5 µg ml − 1), FITC-conjugated anti-pimonidazole 
mouse monoclonal antibody (Natural Pharmacia; ×100 dilution), and anti- 
luciferase goat polyclonal antibody (Promega; 500× dilution) in Tween-TBS 
buffer29,30. HIF-1α was detected with Alexa Fluor 546 rabbit anti-mouse IgG  
(Invitrogen; 2,000× dilution; Figs 2c,d, 3a, and 5j). Meanwhile, luciferase was 
detected with donkey anti-goat IgG conjugated with Alexa Fluor 350 (Invitrogen; 
×2,000 dilution; in Figs 3a and 5j), Alexa Fluor 488 (Invitrogen; 2,000× dilution; in 
Fig. 2c,d), or Alexa Fluor 594 (Invitrogen; in Figs 4d and 5b). The reproducibility  
of each staining was sufficiently confirmed by using enough number of sections 
(See each figure legend for details) and representative results are shown.
FACS analyses. To analyse the luciferase-positive fraction in recurrent tumours, 
91 days after radiation treatment, tumour xenografts were surgically excised, 
minced and treated with a 0.25%. Trypsine solution for 20 min. The resultant single 
cell suspension was treated with DMEM containing 10% FBS, washed with PBS, 
and fixed in 4% paraformaldehyde-PBS. The cells were kept in a PST solution (PBS 
containing 4% Serum and 0.1% triton X-100) on ice for 15 min, then treated with 
anti-luciferase goat polyclonal antibody (Promega; 500× dilution) and Alexa Fluor 
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Figure 5 | Translocation of radio-surviving tumour cells. (a) schematic diagram of treatments in (b). The tumour-bearing mice were treated with 0 ( − ) or  
25 ( + ) Gy of γ-rays on 2 days after tamoxifen injection. YC-1 was administered to suppress radiation-induced activation of HIF-1 (ref. 30). (b) Immunohisto-
chemistry with anti-luciferase (red) and anti-pimonidazole (green) antibodies of the xenografts 4 days after the irradiation. Blue: Hoechst 33342. Bar, 50 µm. 
(c) The percentage of luciferase-positive cells on the indicated days was quantified in the unirradiated and Dmso-injected sections in (b). n = 40 tumour 
cords in 12 sections. (d) The tumour-bearing mice were injected with ( + ) or without ( − ) YC-1 2 days after tamoxifen administration, and subjected to optical 
imaging on the indicated days. Representative images of 12 mice are shown. (e) The numbers of luciferase-positive cells in normoxic regions were quantified 
in the sections of (b). n = 40 tumour cords in 12 sections. **P < 0.01 (student’s t-test). (f) The numbers of luciferase-positive cells in pimonidazole-positive 
regions were quantified in the sections of (b). n = 40 tumour cords in 12 sections. **P < 0.01 (student’s t-test). (g) After transfection with the 5HREp/Cre-ERT2–
ODD gene and CAGp/loxP-polyA-loxP-luciferase gene, antibiotic-resistant WiDr cells were selected with blasticidin. Tumour xenografts, with the resultant stable 
transfectant, were subjected to the same experiment as (a,b). The numbers of luciferase-positive cells in normoxic regions were quantified in the sections. 
n = 40 tumour cords in 12 sections. **P < 0.01 (student’s t-test). (h) The numbers of luciferase-positive cells in pimonidazole-positive regions were quantified  
in the experiment of (g) n = 40 tumour cords in 12 sections. **P < 0.01 (student’s t-test). (i) schematic diagram of treatments in (j). The tumour xenografts, 
with HEK293 transfectant, were subjected to immunohistochemistry 1 day following the 0 ( − ) or 25 Gy ( + ) of radiation. (j) Immunohistochemistry with  
anti-luciferase (blue) and anti-HIF-1α (red) antibodies. Bar, 50 µm. Representative images of 12 xenografts are shown. (k) Percentages of luciferase and  
HIF-1α double-positive cells were quantified in the sections of (j). n = 40 tumour cords in 12 sections. **P < 0.01 (student’s t-test).ARTICLE     
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594 donkey anti-goat IgG (Invitrogen; 2,000× dilution) sequentially, and subjected 
to flow cytometry using FacsCalibur (BD Bioscience) equipped with a 15-mW 
argon laser in the FL1 (530/30) and FL2 (585/30) channels. Dead cells and debris 
were eliminated based on forward-angle and side-scatter. A total of 10,000 events 
were acquired per sample. Reproducibility was confirmed by using 12 independent 
tumour xenografts in each group and representative results are shown.
Statistical analyses. The statistical significance of differences was determined us-
ing Student’s t-test. A P value  < 0.05 was considered to be significant.
Ethics of animal experiments. All animal experiments were approved by the 
Animal Research Committee of Kyoto University, and performed according to 
guidelines governing animal care in Japan. 
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Figure 6 | Therapeutic effect of the combination of radiation and a HIF-1 
inhibitor. (a) The tumour bearing mice were irradiated with γ-rays (25 Gy) 
and treated with or without YC-1 1 min after the irradiation to suppress the 
activation of HIF-1. Kaplan–meier analysis of recurrence-free periods after 
irradiation alone (blue) or after the combination of radiation and a HIF-1 
inhibitor (red). n = 15. (b) During the experiment of (a), relative tumour 
volume was calculated as the ratio of the tumour volume on each day to 
the corresponding volume on day 0. Blue triangle: radiation alone group. 
Red square: radiation & YC-1 group. mean ± s.d. n = 15. *P < 0.05 (student’s 
t-test).ARTICLE
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